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Abstract 
Background: Several members of the TRIM family have been implicated in antiviral defense. Our previous report 
showed that human TRIM11 potently inhibited HIV-1 transduction by reducing the viral reverse transcripts. These 
results prompted us to examine the effect of TRIM11 on HIV-1 uncoating, which is closely related to viral reverse 
transcription.
Results: Using a combination of in vitro binding and in situ proximity ligation assay, we showed that TRIM11 could 
interact with HIV-1 capsid. Overexpression of TRIM11 accelerates HIV-1 uncoating and reduces viral reverse transcrip-
tion indicated by the fate-of-capsid assay and quantitative PCR respectively. Knockdown of TRIM11 enhanced HIV-1 
capsid stability and increased viral reverse transcription. However, the replication of another retrovirus MLV is not 
affected by TRIM11. Moreover, the reverse transcription of HIV-1 mutant bearing capsid G89V showed insensitivity 
to restriction by TRIM11, indicating that the viral determinant of restriction by TRIM11 might reside on capsid. Using 
microtubule dynamics inhibitors, we revealed that microtubule dynamics contributes to TRIM11-mediated HIV-1 
capsid premature disassembly and the reduction of reverse transcription levels. Finally, we demonstrated that TRIM11 
inhibits HIV-1 transduction and accelerates viral uncoating in HIV-1 permissive THP-1-derived macrophages.
Conclusions: We identify TRIM11 as a new HIV-1 capsid binding protein. Our data also reveal that TRIM11 restricts 
HIV-1 reverse transcription by accelerating viral uncoating, and microtubule dynamics is implicated in TRIM11-
imposed block to early events of HIV-1 replication.
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Background
The human tripartite motif containing (TRIM) protein 
family includes approximately 100 members. These pro-
teins have diverse functions ranging from DNA damage 
signaling to antiviral activities. The TRIM family is char-
acterized by its conserved tripartite motif/RBCC motif 
on the N-terminal, which consists of RING, B-Box and 
C-coiled domains. The variable C-terminal is responsible 
for protein diversity. Of the TRIM family proteins which 
have been demonstrated possessing antiviral activities, 
TRIM5α is the best characterized one, which has been 
identified as a potent restriction factor against retrovi-
ruses in a species-specific manner [1, 2]. Rhesus mon-
key TRIM5α (TRIM5αrh) restricts HIV-1 replication via 
multiple mechanisms [1, 3–6]: (1) TRIM5αrh recognizes 
HIV-1 capsid causing premature uncoating and reduced 
viral reverse transcription [1, 3]. (2) TRIM5αrh blocks 
viral DNA nuclear import [4, 5], and (3) it induces rapid 
degradation of HIV-1 gag polyproteins that cause reduc-
tion of virion release in late stage of viral replication [6]. 
In contrast, human TRIM5α (TRIM5αhu) only weakly 
inhibits HIV-1 as it does not recognize the viral capsid 
[3, 7].
After entry into a target cell, the HIV-1 capsid, com-
posed of hexamers and pentamers, undergoes dis-
sociation from the viral complex, a process known as 
uncoating [8]. However, increasing evidences challenge 
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the traditional notion that the core completely disas-
sembles soon after viral entry by proposing the model 
of cytoplasmic uncoating or uncoating at the nuclear 
pores [9, 10]. Meanwhile, the HIV-1 RNA genome is 
reverse transcribed into double stranded DNA, which 
constitutes pre-integration complex with multiple other 
proteins like Vpr and Integrase. Increasing evidences 
suggest that there are multiple interplays between 
viral uncoating and other early steps of HIV-1 replica-
tion cycle. The abnormal viral capsid uncoating often 
causes impairment in HIV-1 replication. HIV-1 prema-
ture uncoating induced by TRIM5αrh and owl monkey 
TRIMCyp has been shown to reduce reverse transcrip-
tion [3, 11]. Dochi et al. reported that the lack of phos-
phorylation of capsid residues Ser16-Pro17, either by 
mutation or by suppression of kinase ERK2 packag-
ing, can impair capsid recognition by a peptidyl-prolyl 
isomerase Pin1, ultimately reducing reverse transcrip-
tion and causing viral core to accumulate in the cyto-
plasm [12]. They hypothesize that a molecular switch 
is needed to promote uncoating and reverse transcrip-
tion [12]. It has been shown that reverse transcription 
inhibitor not only delay uncoating but also increase the 
stability of viral core in the presence of restriction fac-
tors like TRIM5αrh [13, 14]. These results suggest that 
reverse transcription process within the core has the 
ability to impact the kinetics of uncoating. Moreover, 
mutation in capsid protein that enhanced binding to a 
cytopasmic protein, cyclophilin A (CypA), enhanced 
capsid stability and impeded viral DNA nuclear import 
[15]. MxB has recently been identified as a restriction 
factor inhibiting viral DNA entry into nucleus and sta-
bilizing the viral capsid [16]. These results suggest that 
abnormal stability of viral capsid may impede nuclear 
entry of viral DNA. All together, these findings indicate 
that HIV-1 uncoating is a fine process which is regu-
lated by multiple cellular and viral proteins, and is a vul-
nerable target of restriction factors.
A screen of human and mouse TRIM family mem-
bers identified TRIM11 as an inhibitor of both early 
and late stages of HIV-1 replication [17]. We recently 
reported that TRIM11 restricts the early stage of 
HIV-1 replication by reducing viral reverse transcrip-
tion, and that TRIM11 inhibits the LTR activity of 
HIV-1 in an NF-κB dependent way [18]. Accordingly, 
Lee et  al. reported that TRIM11 is a negative regula-
tor of RIG-I-mediated NF-κB activity [19]. However, 
the precise mechanism by which TRIM11 inhibits 
viral reverse transcription is not well characterized. 
The influence of uncoating on reverse transcription 
prompted us to explore whether TRIM11 could rec-
ognize HIV-1 capsid and alter viral capsid stability at 
early stage of postinfection.
Results
TRIM11 interacts with HIV‑1 capsid
We previously reported that TRIM11 reduced HIV-1 
reverse transcription and suppressed viral transduc-
tion [18]. Consideration the close relationship between 
reverse transcription and uncoating described above, we 
hypothesized that TRIM11 might interact with HIV-1 
capsid and accelerate uncoating process. To investigate 
this possibility, we examined the ability of TRIM11 to 
bind in vitro assembled HIV-1 capsid-nucleocapsid (CA-
NC) complexes, which simulate the surface of viral core 
and represent an established model for the assessment 
of HIV-1 capsid interacting proteins [3]. After incuba-
tion of HIV-1 CA-NC complexes with cell lysates bearing 
TRIM5αrh-HA or HA-precipitated cell lysates containing 
TRIM11-HA and TRIM5αhu-HA, we deposited the mix-
tures onto 70  % sucrose cushions and ultracentrifuged 
them for one hour. We found that both TRIM11 and 
TRIM5αrh formed complexes with HIV-1 CA-NC com-
plexes, indicated by the appearance of these proteins in 
the pellet with CA-NC complexes but not in the negative 
control (Fig. 1a). In contrast, TRIM5αhu did not bind to 
HIV CA-NC complexes (Fig. 1a), as previously reported 
[3]. To confirm the interaction between TRIM11 and 
CA-NC complexes, we incubated TRIM11-HA express-
ing cell lysates with an increasing concentration of HIV-1 
CA-NC complexes, and then ultracentrifuged the mix-
tures on sucrose cushions. We found that the amount 
of TRIM11 in the pellet increased with the amount of 
HIV-1 CA-NC complexes (Fig. 1b). These findings indi-
cated that TRIM11 has the ability to associate with 
in vitro assembled HIV-1 CA-NC complexes.
Cell lysates contain multiple proteins that interact 
with HIV-1 capsid. Although TRIM11-HA is abundant, 
chances are that TRIM11 could pellet with CA-NC com-
plexes by interacting with other HIV-1 capsid-interacting 
proteins. To rule out this possibility, we incubated puri-
fied TRIM11 expressed in E. coli with in  vitro assem-
bled HIV-1 CA-NC complexes. Clearly, more TRIM11 
was pelleted in the presence of CA-NC complexes, even 
though it could migrate through 70  % sucrose cushions 
without viral capsid (Fig. 1c). This unexpected pelletable 
TRIM11 could be caused by the high purity and concen-
tration used in this in vitro system, which may form high-
order oligomers. These results suggest that the TRIM11 
could interact with HIV-1 CA-NC complexes without 
other cellular proteins.
To investigate whether TRIM11 could interact with 
HIV-1 capsid during virus infection, we introduced the 
proximity ligation assay (PLA) system that detects pro-
tein–protein interactions closer than 40  nm in  situ. 
HEK293 cells expressing TRIM11-HA or TRIM5αhu-HA 
were infected with HIV-1 or not for 4 h. The cells were 
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Fig. 1 TRIM11 binds to HIV-1 capsid. a The in vitro assembled HIV-1 CA-NC protein was incubated with HA-antibody precipitated mixture from 
HEK293 cell lysates containing the indicated TRIM proteins, and an aliquot of the mixture was retained as input. After centrifugation through 
70 % sucrose cushion, the pellet was resuspended in SDS sample buffer. The input and pellet were analyzed by Western blotting with an anti-HA 
antibody (to detect TRIM proteins) and an anti-p24 antibody (to detect CA-NC). b Similar experiment was carried out as described above with 
HEK293 cell lysates containing TRIM11-HA incubated with increasing amounts of in vitro assembled CA-NC. c Similar experiments were carried out 
as described above with TRIM11 purified from E. Coli. incubated with in vitro assembled CA-NC. d Cells expressing TRIM11-HA or TRIM5αhu-HA were 
infected with or without HIV-1. Four hours post infection, cells were fixed and applied to PLA assay. Nuclei were stained with DAPI (blue), and PLA 
was performed for the association between p24 and TRIM11 (red). Quantification of PLA signal was measured by the average spots per cell of 30 
cells in each sample. Representative results from three separate experiments are shown
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then fixed and incubated with anti-p24 mAbs and anti-
HA rAbs simultaneously followed by PLA probes incu-
bation, ligation and amplification. The negative control 
were incubated with either anti-p24 or anti-HA antibody. 
The interaction events between TRIM11 and p24 were 
revealed as bright fluorescent spots, which resulted in 
an average of 22 spots per cell in TRIM11-HA express-
ing cells while 3 per cell in TRIM5αhu-HA expressing 
cells (Fig.  1d). The negative controls including only one 
antibody incubation and TRIM11-HA expressing cells 
not infected with HIV-1 showed similar dots per cell 
with TRIM5αhu-HA expressing cells infected with HIV-1 
(Fig.  1d). These results indicate that TRIM11 associates 
with HIV-1 capsid during virus infection.
TRIM11 accelerates HIV‑1 uncoating during infection
As previously reported [18], single round infectiv-
ity assay and quantitative PCR indicated that TRIM11 
overexpression significantly inhibited HIV-1 transduc-
tion and reverse transcription, in comparison to vec-
tor control (Fig.  2a, b). Since TRIM11 associates with 
HIV-1 capsid during virus infection, we hypothesized 
that TRIM11 might induce premature uncoating once 
it recognizes viral capsid. To test this hypothesis, we 
challenged TRIM11 overexpressing HEK293 cells with 
HIV-1 for various time and performed the fate-of-cap-
sid assay. We found that pelletable capsid levels were 
significantly lower in TRIM11 overexpressing cells 
than that in vector control cells since 2 h post infection 
Fig. 2 TRIM11 accelerates HIV-1 uncoating during infection. a, b HEK293 cells stably expressing TRIM11-HA and pCDH were infected with 50 ng/
ml (p24gag) HIV-1 and viral transduction was assessed at 24 h post infection by luciferase activity (a) and late reverse transcription levels were 
assessed at 3 h post infection by qPCR (b). c HEK293 cells transfected with pCMV-myc-TRIM11 or empty vector were infected with HIV-1 with or 
without VSV-G envelop at 4 °C for 30 min and then incubated at 37 °C for the indicated time. The cell lysates were centrifuged through 50 % sucrose 
cushion, and the pellet was resuspended in SDS sample buffer. The input and pellet were analyzed by Western blotting with an anti-myc and an 
anti-p24 antibody. The levels of p24 in pelletable and input fractions were measured by densitometry and pellet/input ratio was calculated. d–f 
Similar experiments were carried out as described in a–c, with HEK293 cells in which TRIM11 had been stably knocked down with shRNA. Error bars 
represent the standard deviations from three independent replicates of the same experiments. *P < 0.05
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(Fig.  2c). Furthermore, we used shRNA to knockdown 
TRIM11. As expected, knocking down endogenous 
TRIM11 increased HIV-1 infectivity (Fig.  2d) as well 
as viral reverse transcription (Fig.  2e), and significantly 
enhanced HIV-1 capsid stability (Fig.  2f ). These results 
suggest that TRIM11 accelerates HIV-1 uncoating and 
decreases reverse transcription levels during virus 
infection.
Fig. 3 Comparison of the effects of different TRIM proteins on the early stages of HIV-1 replication. a, b The indicated HEK293 cell lines were 
infected with 50 ng/ml (p24gag) HIV-1 and viral transduction was analyzed by luciferase activity (a) and late reverse transcripts were measured at 
24 h post infection by qPCR (b). c The indicated HEK293 cell lines were infected with HIV-1 for 3 h. Cell lysates were processed for the fate-of-capsid 
assay as described in Fig. 2c. The levels of p24 in pelletable and input fractions were measured by densitometry and pellet/input ratio was calcu-
lated. Error bars represent the standard deviations from three independent replicates. *P < 0.05
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We found that TRIM11 and HIV-1 restriction factor 
TRIM5αrh share the capacity to bind HIV-1 CA-NC com-
plexes and to accelerate uncoating. Although TRIM11 
and TRIM5α belong to the same subfamily, a phylogenetic 
analysis reveals that their amino acid sequences are quite 
different [20]. In addition, TRIM5αhu mediates weak inhi-
bition of the early stage of HIV-1 replication because it 
fails to recognize the viral capsid [3, 7, 21]. To discriminate 
between the effects of the three TRIM proteins on HIV-1 
infection, we compared HIV-1 transduction levels in cells 
overexpressing TRIM11, TRIM5αrh and TRIM5αhu. The 
results showed that HIV-1 transduction was less restricted 
by TRIM11 than TRIM5αrh, whereas it was not affected by 
TRIM5αhu (Fig. 3a). Interestingly, HIV-1 late reverse tran-
scription was reduced to a similar level in both TRIM5αrh 
and TRIM11 overexpressing cells (Fig.  3b). It is reported 
that TRIM5αrh could inhibit not only reverse transcrip-
tion by accelerating viral capsid uncoating, but also nuclear 
accumulation of viral DNA [4, 5]. Our previous study sug-
gested that TRIM11 does not impede viral DNA nuclear 
import [18], which would explain the relatively moderate 
restriction of TRIM11 on HIV-1 transduction (Fig. 3a). Pre-
vious studies showed that TRIM5αrh restriction of HIV-1 
reverse transcription could be restored by proteasome 
inhibitors, despite viral transduction remained blocked [4, 
5]. In order to see if this is the case for TRIM11, we exam-
ined HIV-1 transduction and reverse transcription levels 
impeded by both TRIM11 and TRIM5αrh in the present of 
proteasome inhibitor MG132. In contrast to TRIM5αrh, the 
restriction of TRIM11 on HIV-1 transduction and reverse 
transcription were insensitive to MG132 (Fig. 3c, d), sug-
gesting a different mechanism by which TRIM11 restricts 
early stages of HIV-1 replication compared to TRIM5αrh. 
The results of an in vivo uncoating assay also suggested that 
both TRIM11 and TRIM5αrh cause a premature capsid dis-
assembly (Fig. 3e), whereas TRIM5αhu did not influence the 
stability of HIV-1 capsid. Collectively, both TRIM11 and 
TRIM5αrh inhibit HIV-1 reverse transcription at a compa-
rable level by causing premature viral capsid disassembly.
Microtubule dynamics contributes to TRIM11‑mediated 
premature disassembly of HIV‑1 capsid
TRIM5αrh-mediated restriction of HIV-1 reverse tran-
scription is rescued by proteasome inhibitors [4, 5], 
while TRIM11 is not (Fig.  3d). We therefore exam-
ined whether TRIM11 accelerates HIV-1 uncoating 
through the proteasomal or lysosomal pathway. Cells 
bearing TRIM11-HA or control vector were treated 
with MG132 (proteasomal inhibitor) or chloroquine 
(lysosomal inhibitor) followed by HIV-1 infection. Nei-
ther MG132 nor chloroquine treatment rescued p24 
protein levels in the pellet of TRIM11 overexpressing 
cells to that observed in control cells (Fig.  4a, b). Also 
in TRIM11 knockdown cells, the increased pelletable 
capsid levels were not influenced by either MG132 or 
chloroquine (Fig. 4a, b). These results indicate that nei-
ther proteasome activity nor lysosomal acidification is 
required for TRIM11-mediated accelerating of HIV-1 
uncoating.
Microtubule dynamics has been implicated in both 
HIV-1 uncoating [22] and TRIM5αrh-mediated virus 
restriction [23]. In order to address whether microtubule 
dynamics is involved in TRIM11-mediated premature 
uncoating, we introduced the inhibitors nocodazole and 
taxol, which prevents microtubule polymerization and 
disassembly respectively. We found that compared to 
MG132 and chloroquine, nocodazole treatment resulted 
in similar pelletable capsid levels between TRIM11 over-
expressing cells and control cells (Fig.  4c). As shown in 
Fig.  4d, taxol treatment increased pelletable capsid in 
TRIM11-HA expressing cells to the similar level with 
control cells (Fig.  4d), suggesting that the microtubule 
dynamics disrupted by nocodazole and taxol could fully 
restore core stability in TRIM11 overexpressing cells. 
Meanwhile, both nocodazole and taxol treatment abol-
ished the induction effect of TRIM11 knockdown on 
HIV-1 capsid stability (Fig. 4c, d). As previous reported 
[22, 23], microtubule dynamics disruption imposed by 
nocodazole and taxol treatment could stabilize HIV-1 
capsid during early stage of infection. Here we repre-
sented that the effects of microtubule dynamics inhibi-
tors on HIV-1 capsid are not compromised by TRIM11 
knockdown, suggesting that TRIM11 does not contribute 
to this effect of microtubule dynamics on HIV-1 replica-
tion (Fig. 4c, d).
In accordance with the fate-of-capsid assay, treatment 
with both nocodazole and taxol for 3  h fully rescued 
HIV-1 reverse transcription in TRIM11 overexpressing 
cells (Fig.  4e). Furthermore, both nocodazole and taxol 
treatment abolished the induction effect of TRIM11 
knockdown on viral reverse transcription (Fig. 4f ). These 
results suggest that the effect of TRIM11 on HIV-1 capsid 
stability and viral reverse transcription levels is depend-
ent on microtubule dynamics.
MLV and HIV‑1 capsid mutant G89V is insensitive 
to restriction by TRIM11 on early stage of replication
To assess whether the restriction of TRIM11 on HIV-1 
was specific, we tested the effect of TRIM11 on another 
retrovirus, NB tropic mouse leukemia virus (MLV). 
TRIM11-HA expressing cells and control cells were inoc-
ulated with different amount of MLV or HIV-1. Fourty-
eight hours later, cells lysis were applied to luciferase 
assay to determine viral transduction levels. As shown 
in Fig. 5a, MLV transduction levels were not influenced 
by TRIM11 overexpression while HIV-1 transduction 
Page 7 of 14Yuan et al. Retrovirology  (2016) 13:72 
levels were significantly compromised. In accordance 
with these results, TRIM11 knockdown potentiated 
HIV-1 transduction while did not affect MLV transduc-
tion (Fig.  5b), suggesting that TRIM11 does not inhibit 
MLV transduction as it does to HIV-1.
The results presented above indicated that TRIM11 
recognizes HIV-1 capsid during infection and accelerates 
viral uncoating, resulting in reduced reverse transcrip-
tion. To demonstrate that HIV-1 capsid is the target of 
TRIM11, we introduced several capsid mutations. E45A 
mutant has been reported to increase the capsid stabil-
ity [24], N74D resides in a conserved hydrophobic bind-
ing pocket [25], while P90A, G89V and G94V reside 
in the CypA-binding loop [26]. The reverse transcrip-
tion levels of HIV-1 bearing these capsid mutations in 
TRIM11-HA expressing cells and TRIM11 knockdown 
cells were assessed by realtime PCR. Similar to wild 
type HIV-1, the reverse transcription levels of E45A and 
N74D were restricted in TRIM11-HA expressing cells 
while enhanced in TRIM11 knockdown cells (Fig.  5c), 
Fig. 4 Disruption of microtubule dynamics aborts TRIM11-mediated HIV-1 premature disassembly and reduction of reverse transcription levels. a, 
b The indicated HEK293 cell lines were treated with DMSO, 10 μM MG132 (a) or 10 μM CQ (b) for 3 h before infection with HIV-1. Three hours post 
infection, cell lysates were processed for the fate-of-capsid assay as described in Fig. 2c. c, d The indicated cell lines were infected with HIV-1 in the 
presence of DMSO, 0.1 μM nocodazole (c) and 0.1 μM taxol (d) for 3 h. Cell lysates were processed for the-fate-of capsid assay as described in Fig. 2c. 
e, f HEK293 cells expressing TRIM11-HA and vector (e), HEK293 cells stably knocked down TRIM11 (f) were infected with 50 ng/ml (p24gag) HIV-1 in 
the presence of DMSO, 0.1 μM nocodazole and 0.1 μM taxol and analyzed by qPCR for late reverse transcripts at 3 h post infection. Error bars repre-
sent the standard deviations from three independent replicates. *P < 0.05
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Fig. 5 MLV and HIV-1 bearing capsid G89V mutation are insensitive to restriction by TRIM11 on the early stage of replication. a HEK293 cells 
expressing TRIM11-HA or empty vector pCDH were infected with different amount of HIV-1 or MLV, and viral transduction was assessed at 24 or 48 h 
post infection by luciferase activity. b Similar experiments were carried out as described in a, with HEK293 cells in which TRIM11 expression levels 
were stably knocked down with shRNA-1 specific to TRIM11. c The indicated HEK293 cell lines were infected with 20 ng/ml (p24gag) wild type HIV-1 
as well as different capsid mutants and late reverse transcription levels were assessed at 6 h post infection by qPCR. Error bars represent the standard 
deviations from three independent replicates. *P < 0.05
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indicating that the effect of TRIM11 on HIV-1 early 
stages of replication probably does not relate to capsid 
stability or the hydrophobic binding pocket. In contrast, 
the effect of TRIM11 on HIV-1 reverse transcription was 
abolished by capsid mutation G89V, and compromised by 
capsid mutation P90A (Fig. 5c). Meanwhile, another cap-
sid mutant G94V that also resides on the CypA-binding 
loop was still sensitive to restriction of TRIM11 (Fig. 5c). 
Thus, it is premature to conclude that TRIM11 targets 
the CypA-binding loop of HIV-1 capsid. However, these 
results strongly suggested that TRIM11 might target viral 
capsid during early stages of HIV-1 replication.
TRIM11 interferes with early steps of viral replication 
in HIV‑1 permissive cells
To determine the effect of TRIM11 on HIV-1 replica-
tion in permissive cells, we first measured the expres-
sion of TRIM11 in HEK293, THP-1, THP-1-derived 
macrophages and Jurkat cells. The results showed that 
TRIM11 expresses at similar levels in these cells (Addi-
tional file 1: Fig. S1). Then we constructed TRIM11 over-
expressing and control THP-1 cell lines, which were 
inoculated with increasing amounts of HIV-1 follow-
ing PMA treatment. Forty-eight hours post infection, 
luciferase activity was measured to determine HIV-1 
transduction. In contrast to control vectors, TRIM11 
overexpression substantially reduced HIV-1 transduction 
(Fig. 6a) and realtime PCR indicated that TRIM11 over-
expression decreased viral reverse transcription levels in 
THP-1 derived macrophages (Fig. 6b). The fate-of-capsid 
assay indicated that TRIM11 overexpression reduced the 
level of assembled viral capsid by about 30 % at 1 h post 
HIV-1 infection (Fig. 6c). To assess whether physiological 
levels of TRIM11 in THP-1 cells potentiates HIV-1 rep-
lication, we constructed a TRIM11 knockdown THP-1 
cell line using the same shRNA as we did in HEK293 
cells. In accordance with the results above, knockdown 
of TRIM11 substantially enhanced HIV-1 transduction 
regardless of the inoculation concentration (Fig.  6d). 
Furthermore, knockdown of TRIM11 enhanced HIV-1 
reverse transcription levels (Fig. 6e) as well as HIV-1 cap-
sid stability by about 50 % at 1 h post infection (Fig. 6f ). 
Taken together, these results suggest that TRIM11 blocks 
early steps of HIV-1 replication and accelerates viral 
uncoating in both THP-1-derived macrophages and 
HEK293 cells.
Discussion
TRIM11 is reported to interfere with both early and 
late stages of viral replication [17, 18]. We previously 
reported that TRIM11 inhibits HIV-1 reverse transcrip-
tion during early steps of the viral replication cycle [18]. 
However, the mechanism by which TRIM11 decreases 
viral DNA is still unclear. In this study, we demonstrated 
that TRIM11 both purified from E. coli. and expressed 
in cells interacts with in  vitro assembled HIV-1 capsid. 
Importantly, the PLA assay showed that TRIM11 asso-
ciates with HIV-1 capsid during viral infection. We then 
revealed that TRIM11 accelerates HIV-1 uncoating dur-
ing viral infection in both HEK293 cells and THP-1-de-
rived macrophages. The effect of TRIM11 on uncoating is 
dependent on microtubule dynamics, whereas independ-
ent of proteasomal or lysosomal pathway. All of these 
findings support the restriction of HIV-1 transduction 
by TRIM11, while MLV transduction is not influenced 
by TRIM11. The HIV-1 CA mutant G89V is insensitive 
to the effect of TRIM11, which strengthened the possibil-
ity that the capsid of HIV-1 could be the determinant for 
restriction by TRIM11. Thus, our work presents the first 
human TRIM family member that recognizes HIV-1 cap-
sid and accelerates its uncoating.
Multiple HIV-1 capsid binding proteins have been 
identified [15, 16, 25, 27–30], most of which, like CSPF6, 
NUP153, NUP358, TNPO3 and CypA, were shown as 
dependency factors for HIV-1 replication [25, 28–30]. 
These factors aid properly uncoating of HIV-1 capsid 
or escorting viral DNA into nucleus. In the other side, 
some capsid-binding proteins could perturb uncoating 
and impede HIV-1 replication. MxB was identified as an 
IFN-β inducible restriction factor that could block viral 
DNA nuclear entry by interacting with HIV-1 capsid to 
increase its stability [16]. In this study, we introduced 
TRIM11 as a new HIV-1 capsid binding factor that will 
tilt the balance of uncoating process in favor of accelerat-
ing when it is overexpressed in cells, which will result in 
reduced viral reverse transcription levels.
TRIM11 is not the only human TRIM family mem-
ber that could associate with HIV-1 capsid. TRIM6 
and TRIM34, which are closely related to TRIM5α in 
sequence similarity, have been reported to bind in vitro 
assembled HIV-1 capsid, but they do not have the abil-
ity to restrict HIV-1 replication [20]. By analysis of exten-
sive TRIM5αrh mutants, Yang et  al., demonstrated that 
binding to HIV-1 capsid is necessary, but not sufficient, 
for HIV-1 restriction [31]. Cytoplasmic body formation 
and E3 ubiquitin ligase activity were also implicated in 
TRIM5αrh-mediated capsid disruption and restriction of 
reverse transcription [32–34]. The restriction activity of 
TRIM5α was recently reported to correlate with its abil-
ity to induce TAK-1 dependent innate immune signal-
ing [35]. Thus, in addition to binding with capsid, some 
domains of TRIM5αrh must function in a cryptic mecha-
nism to accelerate viral capsid uncoating. In accordance 
to these findings, the chimeric proteins TRIM-CypA and 
Trim-NUP153(C), which use different domain for bind-
ing to capsid, sustain the restriction ability of TRIM5αrh 
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[36–38]. Then other than binding to HIV-1 capsid, how 
TRIM11 exerts the function of accelerating uncoating is 
still unknown.
We previously reported that TRIM11 decreased HIV-1 
reverse transcription in a proteasome independent man-
ner [18]. In accordance with this result, here we found 
that the effect of TRIM11 on viral uncoating is inde-
pendent of proteasome. Our findings suggested that the 
mechanism by which TRIM11 accelerates HIV-1 uncoat-
ing is not exactly the same as that of TRIM5αrh which can 
be blocked by MG132 [4, 5]. Furthermore, premature dis-
assembly of HIV-1 imposed by TRIM11 is also independ-
ent of the lysosomal pathway. In contrast, microtubule 
dynamics is essential for TRIM11-mediated uncoating 
and reduction of reverse transcription. Since microtubule 
dynamics are involved in uncoating [22], we speculate 
that this cellular apparatus, that originally supports early 
stages of HIV-1 replication, may be utilized by antiviral 
proteins like TRIM5αrh and human TRIM11 to accelerate 
uncoating.
We compared the effects of TRIM11 and TRIM5αrh on 
viral uncoating, reverse transcription and transduction, 
and found that although they have comparable effects on 
viral reverse transcription, TRIM11 restricts HIV-1 trans-
duction less potently than TRIM5αrh does. We attribute 
this to the fact that TRIM11 lacks ability to impede the 
accumulation of nuclear viral DNA. In addition, HIV-1 
reverse transcription levels were significantly increased 
and the viral capsid was more stable in TRIM11 knock-
down THP-1-derived macrophages, suggesting that 
Fig. 6 TRIM11 restricts HIV-1 early stage of replication in THP-1 cells. a, b THP-1 cells expressing TRIM11-HA or empty vector pCDH were treated 
with 100 nM PMA for 48 h followed by infection with indicated amounts of HIV-1 and viral transduction was analyzed by luciferase activity at 48 h 
post infection (a), and late reverse transcripts were measured by qPCR (b). c The indicated THP-1 cell lines were treated with 100 nM PMA for 48 h 
followed by infection with HIV-1 for 1 h. Cell lysates were processed for the fate-of-capsid assay as described in Fig. 2c. The levels of p24 in pelletable 
and input fractions were measured by densitometry and pellet/input ratio was calculated. c–e Similar experiments were carried out as described in 
a–c, with THP-1 cells in which TRIM11 expression levels were stably knocked down with shRNA-1 specific to TRIM11. Error bars represent the stand-
ard deviations from three independent replicates. *P < 0.05
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physiological levels of TRIM11 in HIV-1 relevant cells 
impede viral reverse transcription by accelerating uncoat-
ing process. Although TRIM11 expression was shown 
negatively correlated with HIV-1 replication in monocytes 
[39], it seems like TRIM11 does not act as a restriction 
factor like TRIM5αrh that can be a barrier for retrovirus 
cross species transmission. Unlike Rhesus macaques, 
human is the natural host of HIV-1, which means the 
virus has evolved well enough to conquer potential obsta-
cles in the host. We previously reported that HIV-1 Vpr 
regulated TRIM11 expression levels bidirectionally [18]. 
However, whether the regulation of TRIM11 by Vpr is a 
strategy used by HIV-1 to overcome the restriction effect 
of TRIM11 remained unclear. We speculate that this 
regulation by Vpr is more relevant to the regulation of 
innate immune signaling, as Vpr has not been reported to 
be involved in HIV-1 uncoating. Another scenario is that 
maybe the restriction of TRIM11 on HIV-1 replication is 
covered by other cellular factors. Thus, changing TRIM11 
expression levels by genetic means trumps the effect 
of other cellular factors, and evidences its influence on 
HIV-1 uncoating process. Further investigation into the 
mechanism by which HIV-1 escapes TRIM11-mediated 
restriction of early replication is needed.
Conclusion
Our data demonstrate that human TRIM11 not only has 
the ability to bind in vitro assembled HIV-1 CA-NC com-
plexes, but also associates with HIV-1 capsid protein dur-
ing virus replication. In addition, we found that, similar 
to rhesus macaque TRIM5α, the capacity of TRIM11 to 
accelerate HIV-1 uncoating and decrease viral reverse 
transcription is dependent on microtubule dynamics. 
Finally, our results showed that in one of HIV-1 target 
cell, THP-1-derived macrophages, TRIM11 exhibits the 
same ability to interfere with early stages of HIV-1 repli-
cation as it does in HEK293 cells. Our work presents the 
first human TRIM family member that accelerates HIV-1 
uncoating by interacting with the capsid, and leads to 
inhibition of HIV-1 reverse transcription.
Methods
Cell culture, reagents and antibodies
HEK293 cells and HEK293T cells were cultured in Dul-
becco’s modified Eagle medium (DMEM, Gibco) con-
taining 10  % fetal bovine serum (FBS, Gibco) and 1  % 
glutamine (Gibco). THP-1 cells and Jurkat cells were 
cultured in Roswell Park Memorial Institute medium 
(RPMI, Gibco) supplemented with 10 % FBS and 1 % glu-
tamine. The cells were cultured at 37 °C with 5 % CO2.
The antibodies and reagents used in this work were 
as follows: anti-HA (Cell signaling technology,CST), 
anti-p24 (Santa Cruz Biotechnology), anti-TRIM11 
(Sigma-Aldrich), anti-Myc (Roche); puromycin and 
MG132 (Sigma-Aldrich), chloroquine (CST), nocodazole 
(Beoytime) and taxol (Tocris Bioscience).
Generation of stable cell lines
C-terminal HA-tagged TRIM5αhu and TRIM5αrh 
were obtained by PCR using cDNA from HEK293 and 
RhFK-4 cells respectively. Then stably overexpress-
ing cell lines were constructed as previously described 
[18]. For the TRIM11 stable knockdown cell lines, the 
shRNA were constructed into pLKO.1 (Ctrl: TTCTCC 
GAACGTGTCACGT, 1:TATTCATCTTTCCCGAGAT, 
2:CTATTACAATTCCTCGGAA). HEK293T cells were 
co-transfected with pLKO.1, psPAX2 and pMD2.G using 
Fugene HD Transfection Regent (Promega). Lentiviruses 
were collected at 48 h after transfection, filtered through 
0.45  μm filters. HEK293 cells or THP-1 cells were 
infected with the lentivirus, and 24 h later infected cells 
were selected in medium containing 1.1 μg/ml puromy-
cin. For THP-1 cells, the selective concentration of puro-
mycin was 2.7 μg/ml.
Generation of HIV‑1 CA mutations
Point mutations in the CA region of NL4-3 were engi-
neered by oligonucleotide-directed single-round PCR. 
Specifically, primers containing the mutations were 
applied for PCR, using pNL4-3.Luc.R-E-plasmid as tem-
plate and KOD-Plus-Neo (TOYOBO) as DNA polymer-
ase. The PCR products were subjected to DpnI (New 
England Biolab) at 37  °C for 4  h, and self-ligated for 
transfection into E. coli. The CA region mutant clones 
were sequenced for confirmation.
Western blotting
HEK293 cells were collected and lysed with cell lysis 
buffer (Beyotime) for 10 min on ice. After centrifuged at 
12,000×g, 4 °C for 10 min, the supernatants were added 
to 5 ×  SDS loading buffer (Beyotime) and incubated at 
95  °C for 10 min. Samples were loaded onto 10 % SDS-
PAGE. The protein concentrations were detected using 
BCA Protein Assay kit (Beyotime). After separation, the 
proteins were transferred to nitrocellulose membranes 
(Bio-rad) and detected by incubation with HRP-conju-
gated antibodies.
Single‑cycle infectivity assay
The HIV-1 pNL4-3.Luc.R-E-plasmid [40], was cotrans-
fected with pVSVG using X-treme HP (Roche) to produce 
Vpr-negative pseudotyped HIV-1 NL4-3.Luc viruses (HIV-
1). The MLV pSra-luc plasmid, which was provided by Dr. 
Guangxia Gao (Institute of Biophysics, Chinese Academy 
of Science), was cotransfected with phit60 and pVSVG 
using X-treme HP. Viruses were collected at 48 and 72  h 
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after transfection. The collected virus was centrifuged for 
30 min at 4500×g, and filtered through 0.45 μm filters. The 
quantity of HIV-1 was assessed with HIV-1 p24 ELISA kit 
(Advanced BioScience Laboratories). HEK293 cells sta-
bly expressing TRIM-HA or knocking down of TRIM11 
were seeded in 12-well plates, and infected with differ-
ent amounts of HIV-1 for 24  h or MLV for 48  h. THP-1 
cells stably expressing TRIM11-HA or knocking down of 
TRIM11 were seeded in 12-well plates in the presence of 
100 nM PMA for 48 h, followed by 48 h inoculation with 
different amounts of HIV-1. Cells were collected and lucif-
erase activity was measured using the Luciferase Assay Sys-
tem (Promega). The luciferase activities were normalized to 
the protein quantity measured by BCA Protein Assay kit.
Relative real time PCR
HEK293 cells stably expressing TRIM-HA proteins 
or knocking down of TRIM11 were seeded in 12-well 
plates, and infected with HIV-1 pretreated with 100 U/
ml DNaseI (TaKaRa) for 30 min at 37 °C. Cells were col-
lected at the indicated times after infection. Genomic 
DNA was extracted with DNA extraction kit (Tian-
gen). Real-time PCR was performed as described pre-
viously [18] using SYBR Select Master Mix (Thermo 
Fisher scientific) with primers for reverse transcripts 
specific for luciferase (Luc-F: AAAAGTTGCGCGG 
AGGAGTT, Luc-R: ATTTGGACTTTCCGCCCTTCT) 
and GAPDH (F: AAGGCTGTGGGCAAGG, R: TGG 
AGGAGTGGGTGTCG).
The fate‑of‑capsid assay
The fate-of-capsid assay was performed as previously 
described [3]. HEK293 cells were seeded in two 10  cm2 
dishes. After the cell density reached 80 %, the cells were 
incubated with HIV-1 pseudotyped viruses with or with-
out VSV-g package for 30  min at 4  °C, and shifted to 
37 °C for the indicated time. THP-1 cells were seeded in 
four 10 cm2 dishes in the presence of 100 nM PMA for 
48 h before infected with HIV-1. The cells were washed 
with ice-cold PBS for three times, and resuspended with 
ice-cold PBS containing 1 mM EDTA, and centrifuged at 
500×g 4 °C for 7 min. The pellets were lysed with 2.65 mL 
hypotonic lysis buffer (10 mM Tris–HCl pH 8.0, 10 mM 
KCl, 1  mM EDTA and Complete protease inhibitor) on 
ice for 15  min. After centrifugation at 1000×g 4  °C for 
4 min, the supernatants were layered onto 9.7 mL 50 % 
sucrose cushion (wt/vol, made in PBS), and ultracen-
trifuged at 120,000×g 4  °C for 2 h in a Beckman SW41 
rotor. After centrifugation, the pellets were resuspended 
in 1 × SDS loading buffer (Bio-rad) from bottom of the 
tubes. The cell lysates before ultracentrifugation were 
taken as input. The cell lysates and pellets were subjected 
to Western blotting with anti-HIV-1-p24 antibody.
In vitro capsid binding assay
HIV-1 CA-NC and TRIM11 encoding sequence was 
constructed into the pGEX-6P-1 vector. After transfor-
mation into E. coli. BL21, HIV-1 CA-NC and TRIM11 
were expressed and purified by a GST affinity column 
chromatography with glutathione sepharose4B (GE 
healthcare). Proteins were cleaved from GST using 
PreScission Protease (GE healthcare). The CA-NC 
protein was assembled in  vitro by mixed with DNA 
oligo-TG50 in assemble buffer (50  mM Tris–HCl, 
pH 8.0, 0.5 mM NaCl). The mixture was incubated at 
4  °C overnight and centrifuged at 8600×g for 5  min. 
The cells expressing TRIM11-HA and TRIM5αhu-HA 
were lysed with hypotonic lysis buffer for 30  min on 
ice and precipitated using Monoclonal Anti-HA-Aga-
rose antibody (Sigma-Aldrich). The cells expressing 
TRIM5αrh-HA were lysed with hypotonic lysis buffer 
for 15  min on ice and centrifuged at 12,000×g for 
10  min. The cell lysate and HA-precipitated mixture 
were incubated with CA-NC protein for 1  h at room 
temperature. For the purified TRIM11 protein, 8 μg 
proteins were used to incubate with in  vitro assem-
bled CA-NC complexes. The mixtures were layered 
onto 70 % sucrose cushion (wt/vol, made in PBS), and 
ultracentrifuged at 100,000×g 4  °C for 1  h in a Beck-
man SW60 rotor. After centrifugation, the pellets were 
resuspended in 1 × SDS loading buffer from bottom of 
the tubes. The cell lysates and pellets were subjected 
to Western blotting with anti-HIV-1-p24 antibody and 
anti-HA antibody. The cell lysates before ultracentrifu-
gation were taken as input.
PLA assays
The PLA detection was carried out using the Duolink 
in situ PLA kit (Sigma-Aldrich) according to the instruc-
tions of the manufacturer. Briefly, cells were fixed by fixa-
tive solution (Beoytime) followed by blocking using the 
Duolink blocking solution (3 drop) at room tempera-
ture for 1  h. Primary antibodies were added at dilution 
of 1:100 (anti-HA) and 1:20 (anti-p24) in 40 μl PBS with 
3 % BSA and 0.3 % Triton X-100 and incubated at 37 °C 
for 1 h. The slides were washed two times with PBS for 
5 min each. After incubation with the secondary antibod-
ies, ligation, amplification and mounting according to the 
instructions, images were acquired using a Nikon A1 MP 
two-photon microscope.
Statistical analyses
The data are presented as the mean ± SD of three inde-
pendent experiments that were performed in triplicate, 
and all data were analyzed using Student’s t test. P < 0.05 
(*) was considered to be statistically significant.
Page 13 of 14Yuan et al. Retrovirology  (2016) 13:72 
Authors’ contributions
Conceived and designed the experiments: TY, BS, RY. Performed the 
experiments: TY, WY. Analyzed the data: TY, WY, KT. Wrote the paper: WY, TY, 
BS. Revised the paper: TY, RY, BS. All authors read and approved the final 
manuscript.
Author details
1 Research Group of HIV Molecular Epidemiology and Virology, Center 
for Emerging Infectious Diseases, The State Key Laboratory of Virology, 
Wuhan Institute of Virology, Chinese Academy of Sciences, Xiaohongshan 
44, Wuhan 430071, People’s Republic of China. 2 Department of Pathology, 
National Institute of Infectious Diseases, Tokyo, Japan. 
Acknowledgements
The authors would like to thank Dr. Guangxia Gao (Institute of Biophysics, Chi-
nese Academy of Science) for kindly providing the MLV proviral plasmid and 
the Key Laboratory on Emerging Infectious Diseases and Biosafety in Wuhan 
and The Core Facility and Technical Support, Wuhan Institute of Virology.
Competing interests
The authors declare that they have no competing interests.
Funding
This study was supported by Grants from the National Natural Science Foun-
dation of China (Grant 31470270 to Binlian Sun) and Deutsche Forschungsge-
meinschaft (Transregio TRR60),National Natural Science Foundation of China 
(81461130019). The funders had no role in study design, data collection and 
interpretation, or the decision to submit the work for publication.
Received: 25 March 2016   Accepted: 28 September 2016
References
 1. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The 
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old 
World monkeys. Nature. 2004;427(6977):848–53.
 2. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotrans-
position into TRIM5 explains owl monkey resistance to HIV-1. Nature. 
2004;430(6999):569–73.
 3. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. 
Specific recognition and accelerated uncoating of retroviral cap-
sids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA. 
2006;103(14):5514–9.
 4. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome 
inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse tran-
scription and infection. Proc Natl Acad Sci USA. 2006;103(19):7465–70.
 5. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, Hope TJ. 
Proteasome inhibition reveals that a functional preintegration complex 
intermediate can be generated during restriction by diverse TRIM5 
proteins. J Virol. 2006;80(19):9754–60.
 6. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Rhesus monkey TRIM5alpha 
restricts HIV-1 production through rapid degradation of viral Gag poly-
proteins. Nat Med. 2007;13(5):631–5.
 7. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY 
domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol. 
2005;15(1):73–8.
 8. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell 
Death Differ. 2003;10(1):45–65.
Additional file
Additional file 1: Figure S1. TRIM11 expression levels in different cells. 
HEK293, THP-1, PMA treated THP-1 cells and Jurkat cells were lysed with 
cell lysis buffer. After centrifugation, the supernatants were subjected to 
western blotting for detection of TRIM11 expression levels.
 9. Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 
infection. Nat Rev Microbiol. 2015;13(8):471–83.
 10. Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse 
transcription and nuclear entry. Curr Opin Virol. 2014;4:32–6.
 11. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, et al. RING domain muta-
tions uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse 
transcription and acceleration of uncoating. J Virol. 2012;86(3):1717–27.
 12. Dochi T, Nakano T, Inoue M, Takamune N, Shoji S, Sano K, et al. Phos-
phorylation of human immunodeficiency virus type 1 capsid protein at 
serine 16, required for peptidyl-prolyl isomerase-dependent uncoating, is 
mediated by virion-incorporated extracellular signal-regulated kinase 2. J 
Gen Virol. 2014;95(Pt 5):1156–66.
 13. Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship 
between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci 
USA. 2011;108(24):9975–80.
 14. Yang Y, Fricke T, Diaz-Griffero F. Inhibition of reverse transcriptase activity 
increases stability of the HIV-1 core. J Virol. 2013;87(1):683–7.
 15. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The cap-
sids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by 
the innate sensor cGAS in dendritic cells. Immunity. 2013;39(6):1132–42.
 16. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Camp-
bell EM, et al. MxB binds to the HIV-1 core and prevents the uncoating 
process of HIV-1. Retrovirology. 2014;11:68.
 17. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases 
interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 
2008;4(2):e16.
 18. Yuan T, Yao W, Huang F, Sun B, Yang R. The human antiviral factor TRIM11 
is under the regulation of HIV-1 Vpr. PLoS ONE. 2014;9(8):e104269.
 19. Lee Y, Song B, Park C, Kwon KS. TRIM11 negatively regulates IFN-
beta production and antiviral activity by targeting TBK1. PLoS ONE. 
2013;8(5):e63255.
 20. Li X, Gold B, O’HUigin C, Diaz-Griffero F, Song B, Si Z, et al. Unique features 
of TRIM5alpha among closely related human TRIM family members. Virol-
ogy. 2007;360(2):419–33.
 21. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRI-
M5alpha identifies a critical species-specific retroviral restriction domain. 
Proc Natl Acad Sci USA. 2005;102(8):2832–7.
 22. Lukic Z, Dharan A, Fricke T, Diaz-Griffero F, Campbell EM. HIV-1 uncoating 
is facilitated by dynein and kinesin 1. J Virol. 2014;88(23):13613–25.
 23. Pawlica P, Le Sage V, Poccardi N, Tremblay MJ, Mouland AJ, Berthoux L. 
Functional evidence for the involvement of microtubules and dynein 
motor complexes in TRIM5alpha-mediated restriction of retroviruses. J 
Virol. 2014;88(10):5661–76.
 24. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a 
human immunodeficiency virus type 1 core of optimal stability is crucial 
for viral replication. J Virol. 2002;76(11):5667–77.
 25. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, et al. 
CPSF6 defines a conserved capsid interface that modulates HIV-1 replica-
tion. PLoS Pathog. 2012;8(8):e1002896.
 26. Liu Z, Pan Q, Liang Z, Qiao W, Cen S, Liang C. The highly polymorphic 
cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to 
MxB. Retrovirology. 2015;12(1):1.
 27. Henning MS, Morham SG, Goff SP, Naghavi MH. PDZD8 is a novel 
Gag-interacting factor that promotes retroviral infection. J Virol. 
2010;84(17):8990–5.
 28. Bichel K, Price AJ, Schaller T, Towers GJ, Freund SM, James LC. HIV-1 capsid 
undergoes coupled binding and isomerization by the nuclear pore 
protein NUP358. Retrovirology. 2013;10:81.
 29. Di Nunzio F, Fricke T, Miccio A, Valle-Casuso JC, Perez P, Souque P, et al. 
Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps 
of HIV-1 replication. Virology. 2013;440(1):8–18.
 30. De Iaco A, Luban J. Cyclophilin A promotes HIV-1 reverse transcription 
but its effect on transduction correlates best with its effect on nuclear 
entry of viral cDNA. Retrovirology. 2014;11:11.
 31. Yang Y, Brandariz-Nunez A, Fricke T, Ivanov DN, Sarnak Z, Diaz-Griffero F. 
Binding of the rhesus TRIM5alpha PRYSPRY domain to capsid is necessary 
but not sufficient for HIV-1 restriction. Virology. 2014;448:217–28.
 32. Sastri J, O’Connor C, Danielson CM, McRaven M, Perez P, Diaz-Griffero F, 
et al. Identification of residues within the L2 region of rhesus TRIM5alpha 
that are required for retroviral restriction and cytoplasmic body localiza-
tion. Virology. 2010;405(1):259–66.
Page 14 of 14Yuan et al. Retrovirology  (2016) 13:72 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 33. Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, et al. 
Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by 
TRIM5alpha(rh): structure of the RING domain of TRIM5alpha. J Virol. 
2011;85(17):8725–37.
 34. Fletcher AJ, Christensen DE, Nelson C, Tan CP, Schaller T, Lehner PJ, et al. 
TRIM5alpha requires Ube2 W to anchor Lys63-linked ubiquitin chains and 
restrict reverse transcription. EMBO J. 2015;34(15):2078–95.
 35. Lascano J, Uchil PD, Mothes W, Luban J. TRIM5 Retroviral Restriction Activ-
ity Correlates with the Ability To Induce Innate Immune Signaling. J Virol. 
2015;90(1):308–16.
 36. Yap MW, Dodding MP, Stoye JP. Trim-cyclophilin A fusion proteins can 
restrict human immunodeficiency virus type 1 infection at two distinct 
phases in the viral life cycle. J Virol. 2006;80(8):4061–7.
 37. Langelier CR, Sandrin V, Eckert DM, Christensen DE, Chandrasekaran V, 
Alam SL, et al. Biochemical characterization of a recombinant TRIM5alpha 
protein that restricts human immunodeficiency virus type 1 replication. J 
Virol. 2008;82(23):11682–94.
 38. Matreyek KA, Yucel SS, Li X, Engelman A. Nucleoporin NUP153 
phenylalanine-glycine motifs engage a common binding pocket within 
the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog. 
2013;9(10):e1003693.
 39. Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori DC, Nixon DF, Pillai SK. 
Effects of cellular activation on anti-HIV-1 restriction factor expression 
profile in primary cells. J Virol. 2013;87(21):11924–9.
 40. Zhou D, Wang Y, Tokunaga K, Huang F, Sun B, Yang R. The HIV-1 acces-
sory protein Vpr induces the degradation of the anti-HIV-1 agent 
APOBEC3G through a VprBP-mediated proteasomal pathway. Virus Res. 
2015;195:25–34.
